Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
In patients with progressive fibrosing interstitial lung diseases, the annual rate of decline in the FVC was significantly lower among patients who received nintedanib than amon...
Publications
View AllNintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Among patients with ILD associated with systemic sclerosis, the annual rate of decline in FVC was lower with nintedanib than with placebo; no clinical benefit of nintedanib was ...
Affiliated Researchers
Institution Info
- Type
- company
- Country
- HK
- Publications
- 2
- Citations
- 3,560
External Links
Identifiers
- ROR
- https://ror.org/05hczvf86